Abstracts Archive - Page 2485 of 2607 - ACR Meeting Abstracts

Abstract Number: 1791 • 2012 ACR/ARHP Annual Meeting
Different Mechanisms Responsible for IVIG Inhibition of Immune Complex Versus TLR Stimulated Interferon-Alpha
Alice Wiedeman¹, Fabian Käsermann², Sylvia Miescher² and Keith B. Elkon³, ¹Department of Immunology, University of Washington, Seattle, WA, ²CSL Behring, Bern, Switzerland, ³Rheumatology Box 356428, University of Washington, Seattle, WA
Background/Purpose: SLE immune complexes (IC) induce IFN-α production by stimulation of TLR7 and 9 in plasmacytoid dendritic cells (pDC). Serum from normal human donors…
Abstract Number: 1792 • 2012 ACR/ARHP Annual Meeting
Identification of the Antimicrobial Peptide LL-37 As a Potential Mediator of Synovial Inflammation in Rheumatoid Arthritis
Petra Neregård¹, Marianne Engström¹, Erik Af Klint¹, Birgitta Agerberth² and Anca Catrina³, ¹Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Department of Medical Biochemistry and Biophysics, Chemistry I, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: LL-37, a member of the cathelicidin family of host defense peptides, has a broad range of antimicrobial and immunomodulatory effects that potentially can have…
Abstract Number: 1793 • 2012 ACR/ARHP Annual Meeting
The Cyclooxygenase/Prostaglandin-E₂ Pathway Is Critical for Autocrine IL-17A Production by Th17 Cells Upon Synovial Fibroblast Interaction
Sandra M.J. Paulissen¹, Jan Piet van Hamburg², Nadine Davelaar³, Patrick S. Asmawidjaja³, Johanna M.W. Hazes⁴ and Erik Lubberts³, ¹Immunology, Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ²Rheumatology, Erasmus MC, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Recently, we have shown that Th17, but not Th1 cells, from patients with early rheumatoid arthritis (RA) are potent activators of RA synovial fibroblasts…
Abstract Number: 1794 • 2012 ACR/ARHP Annual Meeting
Matrix Metalloproteinase 3 and Acute Phase Proteins As Markers of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis
Mahmood MTM Ally¹, Bridget Hodkinson², Pieter W.A Meyer¹, Eustasius Musenge³, Mohammed Tikly⁴ and Ronald Anderson¹, ¹University of Pretoria, Pretoria, South Africa, ²Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, ³University of Witwatersrand, Johannesburg, South Africa, ⁴Rheumatology, Division of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Although matrix metalloproteinase-3 (MMP-3) is believed to be intimately involved in the immunopathogenesis of rheumatoid arthritis (RA), relatively little is known about its relationships…
Abstract Number: 1795 • 2012 ACR/ARHP Annual Meeting
Correction for Basophil and Monocyte Frequencies Identifies Specific Gene Expression Differences Associated with SLE Disease Flare: Interim Report From the Bold (Biomarkers of Lupus Disease) Study
Mikhail G. Dozmorov¹, Nicolas Dominguez², Stan Kamp³, Cory Giles², Jonathan D. Wren⁴, Sudhakar T. Sridharan⁵, Joan T. Merrill³, Judith A. James⁶ and Joel M. Guthridge², ¹Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵BioTherapeutics R&D, Pfizer Inc, Collegeville, PA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Heterogeneity of clinical manifestations and pathogenic mechanisms has complicated treatment of SLE patients. The BOLD study allows evaluation of gene expression changes associated with…
Abstract Number: 1796 • 2012 ACR/ARHP Annual Meeting
Anti-IL-20 Targets Local Tissue Inflammation As Opposed to Systemic Inflammation
Amanda L. Blasius¹, Joshua N. Beilke¹, Hal Blumberg¹, John Bui¹, Jennifer H. Cox¹, Tom Cox¹, Heidi J. Jessup¹, Phillip L. Kong¹, Steven D. Levin¹, Valerie H. Odegard¹, Jason A. Stucky¹, Evan P. Thomas¹, Joseph A. Wahle¹ and John Rømer², ¹Biopharmaceuticals Research Unit, Novo Nordisk Inflammation Research Center, Seattle, WA, ²Biopharmaceuticals Research Unit, Novo Nordisk, Måløv, Denmark
Background/Purpose: In a recent Phase 2a clinical trial in patients with rheumatoid arthritis, the novel human anti-IL-20 monoclonal antibody NNC0109-0012 was shown to reduce…
Abstract Number: 1797 • 2012 ACR/ARHP Annual Meeting
Wnt Signaling Pathway Status, Determined by Serum Dkk-1 and R-Spondin 1 Levels, in Rheumatoid Arthritis and Ankylosing Spondylitis
Byoong Yong Choi¹, Hyon Joung Cho¹, Eun Ha Kang², Yeong Wook Song³ and Yun Jong Lee¹, ¹Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Internal Medicine, Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Dickkopf-1 (Dkk-1), known as inhibitor of Wnt signaling pathway, is involved in joint damage in inflammatory arthritis. While R-spondin 1 (Rspo1) reported to protect…
Abstract Number: 1758 • 2012 ACR/ARHP Annual Meeting
Serum BAFF Levels and Relationship with BAFF Binding Receptors in Patients with Rheumatoid Arthritis Relapsing After B Cell Depletion Therapy
Elena Becerra¹, Inmaculada de la Torre², Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College London, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: B-cell-activating-factor (BAFF) coordinates differentiation of B cells into immunoglobulin secreting cells (ISC) by binding to 3 different receptors (BBRs), namely BAFF-R, transmembrane activator and…
Abstract Number: 1759 • 2012 ACR/ARHP Annual Meeting
Expression of Surface APRIL and Its Receptor, TACI, Is Upregulated On B Cells From Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients
Abby Jones Weldon¹, Sheri Hsu², Seyed K. Nazeri³, Saru Sachdeva², Jennifer Gonzalez⁴, Andrea D. Parra⁵, Abigail Benitez¹, Keith K. Colburn⁶, Ioana Moldovan⁷ and Kimberly J. Payne⁸, ¹Microbiology and Molecular Genetics, Loma Linda University, Loma Linda, CA, ²Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ³Rheumatology, Loma Lida University Medical Center, Loma Lida, CA, ⁴Center of Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁵Center for Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁶Dept Med - Rheum Sect, Loma Linda Univ Medical Center, Loma Linda, CA, ⁷Loma Linda Univ Medical Center, Loma Linda, CA, ⁸Pathology and Human Anatomy, Loma Linda University, Loma Linda, CA
Background/Purpose: Autoimmune disease affects more than 23 million Americans. Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) are chronic, systemic B-cell mediated autoimmune diseases. During…
Abstract Number: 1760 • 2012 ACR/ARHP Annual Meeting
A Gene Expression Signature to Monitor Depletion of Plasma Cells Following MEDI-551 (anti-CD19) Administration
Katie Streicher¹, Chris Morehouse¹, Christopher Groves², Bhargavi Rajan², Fernanda Pilataxi¹, Kim Lehmann¹, Philip Brohawn¹, Kathleen McKeever³, Volker Knappertz⁴, Ronald Herbst², Yihong Yao¹ and Koustubh Ranade¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune, Gaithersburg, MD, ⁴Clinical, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Production of pathogenic autoantibodies by inappropriately self-reactive plasma cells (PC) is a hallmark of autoimmune diseases. MEDI-551 is an anti-CD19 antibody which is expected…
Abstract Number: 1761 • 2012 ACR/ARHP Annual Meeting
Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Monoclonal Antibody That Co-Engages the B Cell Antigen Receptor and the FcγRIIb Inhibitory Receptor
Seung Y. Chu¹, Karen Yeter², Roshan Kotha³, Erik Pong¹, Yvonne Miranda¹, Hsing Chen¹, Sung-Hyung Lee¹, Irene Leung¹, John R. Desjarlais¹, William Stohl² and David E. Szymkowski⁴, ¹Xencor, Inc., Monrovia, CA, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁴Biotherapeutics, Xencor, Inc., Monrovia, CA
Background/Purpose: XmAb®5871 is a humanized and Fc-engineered antibody that coengages CD19, part of the B cell receptor (BCR) complex, with the inhibitory receptor FcγRIIb (CD32b).…
Abstract Number: 1762 • 2012 ACR/ARHP Annual Meeting
IL-6 Receptor Inhibition by Tocilizumab Modulates Double Negative (CD19+IgD-CD27-) B Cells in RA
Zafar Mahmood¹, Khalid Muhammad¹, Petra Roll², Stefan Kleinert³, Thomas Dörner⁴ and Hans Peter Tony⁵, ¹Department of Medicine II, Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ²Department of Medicine II, Rheumatology/Clinical immunology, University of Würzburg, Würzburg, Germany, ³Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, ⁴CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵Rheumatology/Immunology, University of Würzburg, Würzburg, Germany
Background/Purpose: Double negative (CD19+IgD-CD27-) B cells have been reported to be part of human memory B cell compartment. Detailed studies of DN B cells in…
Abstract Number: 1763 • 2012 ACR/ARHP Annual Meeting
The Role of SYK in Human B CELL Activation and Its Relevance to Autoimmune Diseases
Shigeru Iwata¹, Kunihiro Yamaoka¹, Hiroaki Niiro², Kazuhisa Nakano¹, Sheau-Pey Wang¹, Koichi Akashi² and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan, ²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Fukuoka, Japan
Background/Purpose: B cells play a pivotal role in pathological processes of autoimmune diseases. Spleen tyrosine kinase (Syk) functions as a key molecule in B-cell receptor…
Abstract Number: 1764 • 2012 ACR/ARHP Annual Meeting
B Cells in Early Rheumatoid Arthritis: ZAP-70 More Than SYK Characterize Seropositive Disease
Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Laura Bosello, Angela Carbonella, Silvia Canestri and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: B cells are involved as central players in the pathogenesis of rheumatoid arthritis (RA). Our aim was to define whether a specific B cell…
Abstract Number: 1765 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Is Associated with Signaling Alterations in Naturally Occurring Autoreactive B-Lymphocytes
Taras Lyubchenko¹, Ganna Liubchenko², Holly C. Appleberry², Christopher C. Striebich², Karen E. Franklin², Lezlie A. Derber³ and V. Michael Holers⁴, ¹Medicine, University of Colorado Denver, Aurora, CO, ²University of Colorado Denver, Aurora, CO, ³Division of Rheumatology, University of Colorado Denver, Aurora, CO, ⁴Rheumatology Division, University of Colorado Denver, Aurora, CO
Background/Purpose: Alterations in B cell immune tolerance are important in the development of autoimmune rheumatoid arthritis (RA). Recent studies in healthy human subjects have identified…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].